Research Keyword: antifungal susceptibility

Antifungal efficacy of caffeic acid and nano-caffeic acid particles against candidiasis: an in vitro study

Researchers developed a nano-particle form of caffeic acid, a natural compound found in coffee and tea, to treat oral yeast infections (candidiasis). The nano-version showed better antifungal activity than regular caffeic acid, though not as strong as prescription antifungal drugs. Since it comes from plants with fewer side effects, it could offer an alternative treatment option for patients with candidiasis.

Read More »

The In vitro Effect of Nanoliposomal Amphotericin B Against Rhizopus arrhizus Isolated From COVID-19-Associated Mucormycosis Patients

Scientists tested a new nano-formulation of the antifungal drug amphotericin B against a dangerous fungus (Rhizopus arrhizus) that infected COVID-19 patients with mucormycosis. The nanoliposomal version of the drug worked much better than regular amphotericin B and other antifungal medications currently used, showing much lower concentrations needed to kill the fungus. This research suggests the new nano-formulation could be a more effective treatment option for patients with this serious COVID-19 related fungal infection.

Read More »

Azole Resistance in Aspergillus Species Isolated from Clinical Samples: A Nine-Year Single-Center Study in Turkey (2015–2023)

This study examined azole antifungal resistance in fungal infections from a Turkish hospital over nine years. Researchers tested 200 Aspergillus fungal isolates and found that 7% showed resistance to azole medications, with 11% of Aspergillus fumigatus showing resistance. The findings highlight the ongoing challenge of drug-resistant fungal infections and the importance of monitoring resistance patterns to improve treatment decisions for serious fungal infections.

Read More »

Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018–2023)

This research examined dangerous mold infections (Mucormycosis) that became more common after COVID-19. Scientists identified the types of molds causing these infections in Iran by testing 116 patient samples and 65 soil samples from across the country. They tested these molds against 13 different antifungal medications to find which drugs work best. The results showed that amphotericin B and posaconazole were the most effective medications, and patient samples were more susceptible to these drugs than environmental soil samples.

Read More »

Clinical and Molecular Characterization of Feline Sporotrichosis in the Brazilian Amazon: PCR-Based Identification of Sporothrix brasiliensis

This research studied a fungal disease called sporotrichosis that affects cats in the Brazilian Amazon and can spread to humans. Most infected cats were young males that roamed freely outdoors and had skin lesions on their faces and paws. Researchers tested different laboratory methods to identify the fungus and found that a specific technique extracted DNA best. They confirmed that Sporothrix brasiliensis was the cause and tested how well common antifungal medications work against it, finding that some drugs work better than others.

Read More »

Trichosporon species bloodstream infections in a tertiary care hospital in the western region of Saudi Arabia: A 7-year retrospective chart review from 2016 to 2022

This study examined a rare but dangerous fungal infection called Trichosporonosis that affects the bloodstream in hospitalized patients. Researchers found that this infection kills about 60% of patients despite treatment with antifungal medications. The infection is often caused by a fungus called Trichosporon asahii and typically occurs in patients with weakened immune systems who are already hospitalized and using catheters.

Read More »

First case of fungemia caused by a rare and pan-echinocandin resistant yeast Sporopachydermia lactativora in China

A 37-year-old woman with leukemia developed a rare blood infection caused by a yeast called Sporopachydermia lactativora, which had never been documented to cause bloodstream infection in China before. This yeast is naturally resistant to a common class of antifungal drugs called echinocandins, making it particularly challenging to treat. However, the patient responded well to a different antifungal medication called voriconazole and fully recovered. The researchers suggest that this unusual yeast should be monitored in hospitals as it could become a more common infection in vulnerable patients.

Read More »

Phaeoacremonium iranianum – a new corneal pathogen

A 66-year-old man developed a serious eye infection from a fungus called Phaeoacremonium iranianum after his eye was scratched by a leaf. This is the first reported case of this fungus causing a corneal infection. Doctors treated the infection with antifungal eye drops and surgery to remove infected tissue, and the patient’s condition improved over time, though with some permanent scarring of the cornea.

Read More »

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources

Candida albicans, a common yeast infection organism, can form tough protective structures called biofilms that resist antifungal medications. This study tested two antifungal drugs (luliconazole and caspofungin) against Candida in both regular form and biofilm form. The results showed that while these drugs work well against regular Candida cells, they are much less effective against biofilms, which require 15-171 times higher doses to be inhibited. The strongest biofilms came from vaginal infections, suggesting that different infection types may require different treatment approaches.

Read More »

Formulation, characterization, and in vitro antifungal evaluation of liposomal terbinafine prepared by the ethanol injection method

Researchers developed a new way to deliver the antifungal drug terbinafine using tiny fat-based particles called liposomes. These particles are designed to carry the drug more effectively to infected tissues while reducing harmful side effects. The optimized formulation showed promise for treating stubborn fungal infections, especially those affecting the brain, with significantly reduced toxicity compared to the drug alone.

Read More »
Scroll to Top